Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 2 November 2009, doi:10.1136/bmj.b4514
Cite this as: BMJ 2009;339:b4514
| The first 150 words of the full text of this article appear below. |
The paper by Kim and Goldie and the editorial by Castle and Scarinci on the cost effectiveness of routinely vaccinating preadolescent boys against human papillomavirus (HPV) ignored some important aspects.1 2 Firstly, by vaccinating girls only, males remain carriers and can transmit the virus to non-vaccinated women and men.
Secondly, the percentage of HPV related diseases is high in some groups of males—for example, oropharyngeal cancer, conjunctival squamous cancer, genital warts, and anal and penile cancers in homosexual, bisexual, and HIV positive subjects.
Thirdly, we recently documented the presence of HPV in ejaculated sperm and its association with reduced sperm motility and male infertility.3 Such cases of reduced sperm motility (asthenozoospermia) are considered idiopathic and are often treated with assisted reproduction techniques. These procedures are expensive and have important psychological effects. Lastly, we recently found HPV in six of 100 cryopreserved semen samples from men with testicular cancer or infertility. Obviously,
Carlo Foresta, professor, Alberto Ferlin, adjunct professor , Andrea Garolla, adjunct professor
1 University of Padova, Department of Histology, Microbiology and Medical Biotechnologies, Section of Clinical Pathology and Centre for Male Gamete Cryopreservation, 35121 Padova, Italy
carlo.foresta@unipd.it